Welcome to our dedicated page for Zynex SEC filings (Ticker: ZYXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zynex, Inc. (ZYXI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and other documents filed with the U.S. Securities and Exchange Commission. Zynex is a medical technology company that develops, manufactures, markets, and sells non-invasive medical devices for pain management and rehabilitation, along with non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for hospitals. Its filings offer detailed insight into this business focus, its financial condition, and its capital structure.
For ZYXI, annual reports on Form 10-K and quarterly reports on Form 10-Q describe revenue from devices and supplies, operating expenses, impairment charges, and risk factors. In 2025, the company also filed a Form 12b-25 explaining a delay in filing its third-quarter Form 10-Q and indicating that it expected to disclose substantial doubt about its ability to continue as a going concern, citing limited cash resources and the impact of payer-related issues.
Current reports on Form 8-K are especially important for understanding Zynex’s recent developments. These filings include disclosures about leadership changes, strategic initiatives, impairment charges at Zynex Monitoring Solutions, and, critically, the company’s voluntary Chapter 11 filings in the United States Bankruptcy Court for the Southern District of Texas. Related 8-Ks describe a restructuring support agreement with holders of its 5.00% Convertible Senior Notes due 2026, details of a debtor-in-possession financing facility, and Nasdaq’s determination to delist Zynex’s common stock as a result of the Chapter 11 cases.
Stock Titan’s platform surfaces these filings in real time as they are posted to EDGAR and pairs them with AI-powered summaries that explain key points in clear language. Users can quickly see what each 8-K addresses, how a 10-K or 10-Q discusses revenue trends, impairment charges, or going-concern language, and where documents reference restructuring milestones and listing status. The filings page also helps users locate information related to Zynex’s convertible notes, debtor-in-possession obligations, and other material agreements disclosed in its reports.
For those analyzing ZYXI, this page offers a structured way to review Zynex’s regulatory history, from its medical device business description to its Chapter 11 restructuring steps and Nasdaq delisting process, with AI-generated highlights to reduce the time needed to interpret complex filings.
Zynex, Inc. filed a Form 12b-25 to notify a delay in its Form 10-Q for the quarter ended September 30, 2025. The company needs additional time to finalize the Q3 financial statements and related disclosures.
Management anticipates the upcoming Form 10-Q will disclose substantial doubt about the company’s ability to continue as a going concern, citing that current cash resources are not sufficient to support planned operations for at least 12 months from the expected issuance date of the Q3 financial statements.
Zynex expects to file the Form 10-Q within the five-day grace period allowed under Rule 12b-25.
Zynex, Inc. reported leadership changes tied to the resignation of Chief Commercial Officer Anna Lucsok. Her resignation was effective October 10, 2025, with separation terms finalized on October 27, 2025.
Under her employment agreement, Ms. Lucsok is entitled to severance, conditioned on her execution, non-revocation, and compliance with a Separation Agreement dated October 27, 2025. The Compensation Committee also approved the accelerated vesting of 60,746 unvested restricted shares previously issued to her, effective as of the Separation Date and subject to the same conditions.
Zynex, Inc. (ZYXI) reported a new director appointment disclosure. A Form 3 initial statement of beneficial ownership was filed indicating the reporting person is a Director and no securities are beneficially owned. The event date is 10/07/2025, and the filing was made by a single reporting person. This is a routine governance filing that establishes the insider’s baseline holdings at zero.
Zynex, Inc. appointed Bret W. Wise to its Board, expanding the board from five to six members effective October 7, 2025. Wise will serve until the 2026 annual meeting and was named Chair of the Audit Committee, and a member of the Compensation and Nominating and Governance Committees.
Director compensation: Wise will receive annual cash retainers of $40,000 (Board), $20,000 (Audit Chair), $7,500 (Compensation Committee), and $5,000 (Nominating and Governance), paid quarterly in arrears and pro‑rated as applicable. He will also receive an initial grant of 20,000 restricted shares and an annual grant of 10,000 restricted shares upon re‑election, vesting quarterly over three years, beginning one quarter after grant, subject to continued service.
Additional updates: Chair Thomas Sandgaard will receive annual retainers of $150,000 (Board Chair) and $250,000 (Technology Committee Chair), paid quarterly in arrears. Chief Commercial Officer Anna Lucsok resigned effective October 10, 2025.
Zynex, Inc. is making a strategic shift for its Zynex Monitoring Solutions (ZMS) business by seeking a commercialization partner for the NiCO™ CO-Oximeter instead of bringing the device to market on its own. As part of this change, the company terminated the positions of a majority of ZMS employees, with substantial cost savings expected from this reduction in force.
Zynex expects pre-tax cash charges of approximately
Zynex, Inc. reported a leadership role change for one of its senior executives. Effective September 16, 2025, Anna Lucsok transitioned from serving as Chief Operating Officer to serving as the company’s Chief Commercial Officer. She will continue as an executive officer, meaning she remains part of the top management team. As part of this change, her prior responsibilities for overseeing manufacturing, information technology, and regulatory matters were re-allocated within the company to other areas or leaders. The filing does not describe changes to compensation or other terms, focusing instead on clarifying her new commercial-focused role.
Vikram Singh Bajaj filed an SEC Form 3 reporting his initial statement of beneficial ownership for Zynex Inc (ZYXI). The reported event date is 08/18/2025. Mr. Bajaj is identified as an officer with the title Chief Financial Officer. The form states no securities are beneficially owned by the reporting person at the time of filing. The form was signed on 09/03/2025.
Steven Lewis Dyson is reported as both Chief Executive Officer and a director of Zynex Inc (ZYXI) on an initial Form 3. The filing discloses that no securities are beneficially owned by the reporting person and that the Form was filed by a single reporting person. The form shows no non‑derivative or derivative holdings and includes the reporting person’s address.
John T. Bibb, listed as both a Director and the company's Chief Legal Officer, filed an Initial Statement of Beneficial Ownership (Form 3) for Zynex Inc (ZYXI) reporting the event date 08/18/2025. The filing explicitly states that no securities are beneficially owned by the reporting person. The form is signed and dated 08/28/2025.
Zynex, Inc. appointed Vikram Bajaj as Chief Financial Officer and Treasurer and John Bibb as Chief Legal Officer and Secretary, effective August 18, 2025. Former CFO Dan Moorhead resigned that day and will leave the company on August 29, 2025.
Bajaj and Bibb each receive a $450,000 annual base salary and are eligible for an annual discretionary bonus targeted at 70% of base pay. Each is granted inducement equity awards with a grant date fair value of $2.5 million in restricted stock vesting after three years and $2.5 million in stock options vesting quarterly over four years, subject to continued employment and certain accelerated vesting triggers. They also receive six months of salary and health benefits plus a pro‑rated bonus if terminated without cause or for good reason. The board expanded from four to five members and elected CEO Steven Dyson as a director without additional compensation.
FAQ
What is the current stock price of Zynex (ZYXI)?
What is the market cap of Zynex (ZYXI)?
